Track ACXP and 10,000+ stocks
Create a free account to build watchlists, compare peers, and value any stock.
- Build and track watchlists
- Compare against peers
- Earnings & price alerts
No credit card required
Acurx Pharmaceuticals LLC
259 Liberty Avenue, Staten Island, NY, United States, 10305
IPO
2021
Employees
4
Industry
Biotechnology
Sector
Healthcare
Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections in the United States. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections. It also develops ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus (MRSA), vancomycin resistant enterococcus (VRE), and drug-resistant streptococcus pneumoniae (DRSP), as well as B. anthracis. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.
Insider Transactions
Quarterly buy vs. sell activity
Sell (left)Buy (right)
Q1 20250+2
2
Analyst Ratings
2 analysts covering
Buy100%recommend buy
Buy
2
Hold
0
Sell
0